Equities

Mersana Therapeutics Inc

Mersana Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.57
  • Today's Change0.02 / 0.78%
  • Shares traded3.72m
  • 1 Year change+97.69%
  • Beta1.4180
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments209281178
Total Receivables, Net030--
Total Inventory------
Prepaid expenses4.978.5111
Other current assets, total------
Total current assets214319189
Property, plant & equipment, net121415
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets--0.182.36
Total assets226334206
LIABILITIES
Accounts payable7.321412
Accrued expenses254631
Notes payable/short-term debt000
Current portion long-term debt/capital leases2.230.240.24
Other current liabilities, total29313.94
Total current liabilities649248
Total long term debt232525
Total debt252525
Deferred income tax------
Minority interest------
Other liabilities, total10212612
Total liabilities18924284
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital863747572
Retained earnings (accumulated deficit)(826)(655)(450)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.01(0.15)--
Total equity3792122
Total liabilities & shareholders' equity226334206
Total common shares outstanding12110574
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.